NCT05237947 2026-03-19
PRISMA
National Cancer Institute (NCI)
Phase 4 Active not recruiting
Clinical Trials
3 trialsNCT02518555 2026-01-07
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03180034 2025-09-04
ESCUDDO
National Cancer Institute (NCI)
Phase 4 Active not recruiting